349 related articles for article (PubMed ID: 11253051)
21. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme.
Vogel TW; Zhuang Z; Li J; Okamoto H; Furuta M; Lee YS; Zeng W; Oldfield EH; Vortmeyer AO; Weil RJ
Clin Cancer Res; 2005 May; 11(10):3624-32. PubMed ID: 15897557
[TBL] [Abstract][Full Text] [Related]
22. [Cellular energetic metabolism of cerebral tissue: metabolic characteristics of glial tumours].
La Schiazza R; Lamari F; Foglietti MJ; Hainque B; Bernard M; Beaudeux JL
Ann Biol Clin (Paris); 2008; 66(2):131-41. PubMed ID: 18390423
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
24. Malignant astrocytic glioma: genetics, biology, and paths to treatment.
Furnari FB; Fenton T; Bachoo RM; Mukasa A; Stommel JM; Stegh A; Hahn WC; Ligon KL; Louis DN; Brennan C; Chin L; DePinho RA; Cavenee WK
Genes Dev; 2007 Nov; 21(21):2683-710. PubMed ID: 17974913
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice.
Kim Y; Hong HH; Lachat Y; Clayton NP; Devereux TR; Melnick RL; Hegi ME; Sills RC
Toxicol Pathol; 2005; 33(3):307-12. PubMed ID: 15814359
[TBL] [Abstract][Full Text] [Related]
26. Review: low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1.
Thangarajh M; Gutmann DH
Neuropathol Appl Neurobiol; 2012 Jun; 38(3):241-53. PubMed ID: 22035280
[TBL] [Abstract][Full Text] [Related]
27. [Genetic alterations of gliomas].
Tabuchi K; Fukuyama K
No To Shinkei; 1997 Mar; 49(3):205-13. PubMed ID: 9125726
[No Abstract] [Full Text] [Related]
28. Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.
Viapiano MS; Bi WL; Piepmeier J; Hockfield S; Matthews RT
Cancer Res; 2005 Aug; 65(15):6726-33. PubMed ID: 16061654
[TBL] [Abstract][Full Text] [Related]
29. Targeting malignant glioma survival signalling to improve clinical outcomes.
Wong ML; Kaye AH; Hovens CM
J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
[TBL] [Abstract][Full Text] [Related]
30. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
[TBL] [Abstract][Full Text] [Related]
31. Hypothesis: cannabinoid therapy for the treatment of gliomas?
Velasco G; Galve-Roperh I; Sánchez C; Blázquez C; Guzmán M
Neuropharmacology; 2004 Sep; 47(3):315-23. PubMed ID: 15275820
[TBL] [Abstract][Full Text] [Related]
32. Mouse models of human cancer as tools in drug development.
Holland EC
Cancer Cell; 2004 Sep; 6(3):197-8. PubMed ID: 15380508
[TBL] [Abstract][Full Text] [Related]
33. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
Hargrave D
Br J Neurosurg; 2009 Aug; 23(4):351-63. PubMed ID: 19637006
[TBL] [Abstract][Full Text] [Related]
34. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment.
Hoelzinger DB; Demuth T; Berens ME
J Natl Cancer Inst; 2007 Nov; 99(21):1583-93. PubMed ID: 17971532
[TBL] [Abstract][Full Text] [Related]
35. Genetically engineered mouse models of diffuse gliomas.
Schmid RS; Vitucci M; Miller CR
Brain Res Bull; 2012 May; 88(1):72-9. PubMed ID: 21684324
[TBL] [Abstract][Full Text] [Related]
36. A mouse model for glioma: biology, pathology, and therapeutic opportunities.
Holland EC
Toxicol Pathol; 2000; 28(1):171-7. PubMed ID: 10669005
[TBL] [Abstract][Full Text] [Related]
37. [Animal models of human glioma: the progress of application and investigation].
Zhu HF; Zhang YX; Zhao XD
Dongwuxue Yanjiu; 2012 Jun; 33(3):337-42. PubMed ID: 22653863
[TBL] [Abstract][Full Text] [Related]
38. Molecular pathogenesis of malignant glial tumors.
Jones TS; Holland EC
Toxicol Pathol; 2011 Jan; 39(1):158-66. PubMed ID: 21078918
[TBL] [Abstract][Full Text] [Related]
39. Malignant glioma: lessons from genomics, mouse models, and stem cells.
Chen J; McKay RM; Parada LF
Cell; 2012 Mar; 149(1):36-47. PubMed ID: 22464322
[TBL] [Abstract][Full Text] [Related]
40. The chemokine network, a newly discovered target in high grade gliomas.
Domanska UM; Kruizinga RC; den Dunnen WF; Timmer-Bosscha H; de Vries EG; Walenkamp AM
Crit Rev Oncol Hematol; 2011 Aug; 79(2):154-63. PubMed ID: 20709564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
